Which Weight-Loss Probiotic Brands Match the Trial Dose?

Named-Strain Probiotic Products for Weight Management: From Clinical Study to Store Shelf

Eight named strain codes across five strain groups anchor most weight-management probiotic marketing: B420, the three-strain SlimBiotics® blend, CECT 8145 (BPL1), two unrelated Lactobacillus gasseri codes, and CGMCC1.3724. Here's the trial behind each one, the retail products that carry it today, and whether the label dose matches what was tested.

Why the exact strain code, not the species name, is what to check

"Contains L. gasseri" or "with clinically studied probiotics" tells you almost nothing on its own. Probiotic effects are strain-specific, not species-specific: a trial on L. gasseri SBT2055 says nothing about a bottle that lists plain "L. gasseri" with no strain code. Dose matters too, and not always in a straight line. When researchers tested two different doses of SBT2055 head-to-head, both beat placebo on visceral fat, but the higher dose wasn't clearly better than the lower one.¹¹ A higher dose on a label doesn't automatically buy a bigger effect. But the logic cuts the other way too: a retail product dosed far below anything tested has no trial evidence behind that specific amount, whatever the strain code on the label says.

B420 (Bifidobacterium animalis subsp. lactis 420): one trial, three different shelf doses

B420 is frequently cited in this category, largely on the strength of one 225-person, six-month randomized trial (Stenman 2016).¹ The trial's pre-specified primary endpoint, relative change from baseline to six months in DXA-measured body fat mass, was analyzed in 199 of the 225 randomized participants and was not significant across all four groups (P = 0.46). In the smaller per-protocol subset, B420 plus a 12 g/day fiber showed a −4.5% difference in fat mass versus placebo (P = 0.02, n = 37 in the combination arm), while B420 alone did not (−3.0% difference versus placebo, P = 0.28, not significant); the placebo group itself gained roughly 1 kg in body weight over the trial. Body weight, a separate measure from fat mass, also showed only a non-significant per-protocol difference versus placebo in the B420-alone group (P = 0.15). A post-hoc factorial analysis, run in the per-protocol population after the trial was unblinded, used both B420-containing arms and both non-B420 arms to estimate the B420 main effect and found a significant difference (−4.0% fat, −2.4 cm waist, P = 0.002 and 0.004); it never compared the B420-alone arm against the B420-plus-fiber arm directly. DuPont Nutrition & Health, now part of IFF,² funded the trial; 5 of the 15 authors, including the lead author, were DuPont employees, and DuPont staff helped draft the study protocol, reports, and data interpretation. Every author or their institution received compensation tied to the study.

Three products show how differently this strain reaches the shelf. Metagenics UltraFlora Control sells it as a single-strain capsule, 10 billion CFU of B-420, one per day.³ Bariatric Advantage FloraVantage Control uses an almost identical formula, the same 10 billion CFU single-strain B420 dose (113.1 mg of the B420 preparation per capsule), and its own product page cites the Stenman trial by name, targeting patients recovering from weight-loss surgery.⁴ Both match the trial's minimum target dose for the B420-alone arm (the trial actually packaged that arm's product higher, at about 1.4 × 10¹⁰ CFU/day, to offset decline in viability over the study, and measured roughly 1.1 × 10¹⁰ CFU/day in returned sachets at the six-month mark). The prespecified four-group primary analysis was null overall, and the B420-alone arm didn't separate from placebo on fat mass in the per-protocol comparison either (P = 0.28); the significant result came from the separate post-hoc factorial analysis, not from the B420-alone arm. Our own WonderBiotics Probiotics for Weight Management takes a different approach. We include B420 among eight named strains, alongside HN019, NCFM, L. rhamnosus GG, and four others, in a blend labeled at 20 billion CFU total, plus dihydroberberine and a lemon fruit extract standardized to 70% eriocitrin as separate Key Ingredients.⁵ Like most multi-strain blends, our label reports that 20 billion CFU total rather than an isolated per-strain dose, so B420's own share isn't broken out separately.

SlimBiotics: a three-strain blend, and a retail formula that's finally traceable to the trial

SlimBiotics® is the trademark for three Lactobacillus fermentum strains (K7-Lb1, K8-Lb1, K11-Lb3). The main human trial, a 180-person randomized study by Laue and colleagues (2023), tested the three strains alone against a synbiotic version (same strains plus acacia fiber) and a placebo over 12 weeks, with body fat mass by bioelectrical impedance as the pre-specified primary endpoint in a 176-person full analysis set.⁶ The overall three-group comparison on that endpoint was significant (P = 0.015); in the follow-up pairwise test, the probiotic-only arm beat placebo (fat mass −0.61 kg versus a 0.13 kg gain, P = 0.039), with secondary improvements in weight (P = 0.012) and waist circumference (P < 0.05). The synbiotic arm missed the fat-mass comparison (P = 0.73) even though its visceral fat result was significant; the authors attributed the weaker synbiotic result to a lower measured count of viable lactobacilli in that version of the product, likely caused by extra moisture from the acacia gum. The probiotic-only sachets were formulated to deliver at least 2 billion CFU per strain at the end of shelf life; the finished probiotic-only product was measured at a total of about 5.46 billion CFU per day across all three strains combined, delivered as two 6 g sachets daily. Slimbiotics GmbH funded the trial, and one author is a co-inventor on the strain patent and acts as a consultant to the company.

The retail product carrying these strains is Culturelle Metabolism + Weight Management with SlimBiotics®, $26.99 for a 30-day, one-capsule-per-day supply.⁷ Culturelle's current Supplement Facts panel lists exactly four strains, Lacticaseibacillus rhamnosus GG plus the three SlimBiotics strains, totaling 12 billion CFU in a 140 mg blend. It does not contain B. animalis subsp. lactis CECT 8145 (BPL1), even though some of Culturelle's own marketing copy on the same page still references that fifth strain from an older formula version. Against the Laue trial, the retail capsule adds LGG, which wasn't in the tested probiotic-only arm, and the label doesn't break out how much of the 12 billion CFU total goes to each of the four strains. The trial's three strains were studied at a measured total of about 5.46 billion CFU combined; 12 billion CFU spread across four strains could plausibly land in that range, but there's no way to confirm the actual split from the label alone.

CECT 8145 (BPL1): the weight-studied strain that now lives in a skin blend

B. animalis subsp. lactis CECT 8145, branded BPL1, comes from a randomized, double-blind, placebo-controlled trial with three arms. Pedret and colleagues (2019) randomized 135 adults with abdominal obesity to placebo, live BPL1, or heat-killed BPL1, each dosed as one capsule per day containing 100 mg of the bacterial preparation standardized to 10¹⁰ CFU (before heat inactivation, for that arm) plus 200 mg maltodextrin; 126 received the allocated intervention (placebo 40, live BPL1 42, heat-killed BPL1 44).⁸ The live and heat-killed forms produced different results. On waist circumference, both improved versus their own baseline (P < 0.05), but only heat-killed beat placebo between groups (P < 0.05); live BPL1 only showed a non-significant downward trend against placebo (P < 0.07). On visceral fat area, in a model adjusted for baseline waist circumference, only heat-killed improved significantly versus its own baseline, and neither arm reached conventional significance against placebo (P = 0.086 for heat-killed, P = 0.120 for live). In exploratory sex-stratified analyses, the significant results were confined to women; the pattern wasn't uniform across every measure. Spain's CDTI public research agency funded the trial, and five of the authors were employees of Biopolis SL/ADM, the company that commercializes the strain.

One current retail product listing the strain is Seed DS-01 Daily Synbiotic, coded SD-CECT8145-SP inside its Dermatological Health Blend, a 36 mg, 3.34 billion AFU sub-blend shared with three other strains.⁹ Seed doesn't break out how much of that shared 36 mg belongs to CECT8145 specifically, doesn't cite the Pedret adiposity data anywhere in its consumer marketing, and positions the entire blend for skin health, not weight. It's also a live-form supplement, and in the Pedret trial the live arm is the one that showed only a non-significant trend against placebo on waist circumference, not the heat-killed arm that reached significance there. CECT8145 shares that 36 mg with three other strains, and Seed measures potency in AFU rather than the CFU the trial used, so the two numbers aren't a validated apples-to-apples comparison; CECT8145's own share of that blend can't exceed 36 mg, well under the trial's single-strain 100 mg dose. Searches of major U.S. retailers and brand sites in September 2026 didn't identify a U.S. direct-to-consumer product offering heat-killed CECT8145/BPL1, the form that beat placebo on waist circumference, anywhere close to the tested dose.

L. gasseri: one species name, two unrelated strain codes, and a lot of labels with no code at all

L. gasseri shows up under at least two unrelated strain codes in weight-management products, plus a fair number of labels that just say "L. gasseri" with no code at all.

SBT2055 has two trials from researchers affiliated with the same Japanese dairy company: an 87-person 2010 study (43 on active fermented milk, 44 on a control version) showing within-group drops in visceral and subcutaneous fat (4.6% and 3.3%) at roughly 100 billion CFU/day (200 g/day at about 5 × 10⁸ CFU/g),¹⁰ and a 210-person 2013 follow-up that tested two much lower doses. Visceral fat, the trial's own pre-specified primary endpoint, was significantly lower than placebo at both doses (P < 0.05), though the two doses performed about the same, with no clear dose-response, and stopping for four weeks attenuated the effect.¹¹ The manufacturer's own measured viable-cell counts for the two dose groups averaged 6.9 × 10⁶ and 7.9 × 10⁷ CFU/g in 200 g/day of fermented milk, working out to roughly 1.4 billion and 15.8 billion CFU/day. Provitalize, sold by BB Company, currently lists SBT2055 as one of three strains (alongside B. breve IDCC4401 and B. animalis subsp. lactis R101-8) plus fructo-oligosaccharide prebiotic, all folded into a single 400 mg "Proprietary Synbiotic Blend" alongside a turmeric-and-moringa complex.¹² The label discloses neither a total CFU count nor a per-strain breakdown, so there's no way to check SBT2055's actual dose against the roughly 1.4-100 billion CFU/day tested across the two trials at all.

BNR17 comes from a 90-person, 12-week trial (Kim 2018) testing two doses against placebo.¹³ Only the high dose (10¹⁰ CFU/day) beat placebo on visceral fat between groups (−21.6 cm², P = 0.012). Waist circumference shrank versus baseline in both dose groups, but neither dose beat placebo on that measure between groups, a distinction marketing copy often blurs. AceBiome, Bioneer's Korean affiliate, licensed BNR17 to UAS Labs for the U.S. market in 2018.¹⁴ Daily Nouri Weight Health combines BNR-17 with L. plantarum UALp-05 and L. rhamnosus GG at $29.99 for a one-capsule, 30-day supply, with subscription pricing around $0.90/day; per-strain CFU isn't disclosed.¹⁵ Daily Nouri's own marketing cites "a waist circumference decrease of 5cm over 12 weeks," a specific figure that doesn't appear in the Kim trial's published abstract; the abstract reports statistical significance but not that centimeter number, so it can't be verified against what's publicly available from the trial.

Uncoded L. gasseri is the hardest category to check, because there's no strain code to look up. Physician's Choice THIN 30, also sold as Physician's Choice Probiotics for Weight Management & Bloating, lists plain "L. gasseri" among six strains and attributes fat-absorption and waist-circumference benefits to it directly on the product page, without citing a specific strain code or trial.¹⁶ That claim can't be tied to either the SBT2055 or BNR17 data above, because there's no way to confirm which strain, if any coded one at all, is actually in the capsule.

CGMCC1.3724 (the "LPR" strain): a documented trial, no verified retail home

CGMCC1.3724, also called LPR, is Lacticaseibacillus rhamnosus dosed at about 3.2 × 10⁸ CFU/day alongside an oligofructose-and-inulin prebiotic in a 2014 trial (Sánchez et al.) of 153 adults on an energy-restricted diet.¹⁷ Twenty-eight of the 153 randomized participants were excluded after randomization for dyslipidemia, and the trial's own intention-to-treat analysis, run on the remaining 125, found no significant difference in weight loss between LPR and placebo overall. The signal that exists is confined to a women-only subgroup: 12-week weight loss of 1.8 kg versus placebo (P = 0.02), a gap that widened by 24 weeks (P = 0.02); by 24 weeks, the LPR group's fat mass had dropped 4.79 kg against a 2.16 kg drop in the placebo group (P = 0.01). Men in the same trial showed no effect (P = 0.53). The active arm also contained the prebiotic alongside the strain, so the weight loss can't be pinned on LPR by itself, and the trial explicitly excluded postmenopausal women. Nestlé Research Center funded the trial, contributed to the study design, ran the fecal analyses and some of the blood analyses, and had staff involved in preparing the manuscript; several authors were Nestlé Research Center employees. As of September 2026, searches of major U.S. retailers and brand sites turned up no mainstream direct-to-consumer product marketing this strain by its CGMCC1.3724 or LPR code.

The strain-to-shelf evidence chain at a glance

Where WonderBiotics fits: a multi-target formula, not a single-strain replica

Perimenopausal and GLP-1 users are usually managing more than one thing at once, appetite, metabolic health, and digestive regularity among them, which is why we built WonderBiotics Probiotics for Weight Management around a multi-strain, multi-target approach rather than replicating one strain at a single high dose. The formula pairs B420 with seven other named strains, including HN019 for gut transit time and stool frequency, alongside dihydroberberine and an eriocitrin-standardized lemon extract as a separate pair of metabolic actives, whose own evidence stands apart from the B420 trial data above.⁵ HN019's role here is digestive regularity, not the weight/adiposity literature covered above, so we're not stretching that strain's evidence to cover a claim it wasn't tested for. As with any multi-strain blend, the label reports total CFU rather than an isolated per-strain dose, the same transparency trade-off every combination product in this article makes. WonderBiotics Probiotics for Weight Management is built for readers who want that strain diversity paired with a second, separately evidenced set of metabolic ingredients working alongside it.

How to run this dose-match check yourself before you buy

• Find the exact strain code on the label. "L. gasseri" alone isn't evidence of anything; SBT2055, BNR17, and other coded strains each have their own separate, non-interchangeable trial data.
• Look up that strain's trial dose, not just whether a trial exists. A strain with real human data at 10¹⁰ CFU/day tells you little about a product dosing it at 10⁹ or leaving it undisclosed.
• Check whether the product discloses a per-strain CFU or just a blend total. Single-strain capsules like UltraFlora Control make this easy to verify; multi-strain blends, including ours, generally don't.
• Re-check formulas periodically. Culturelle's own marketing copy still references a strain its current label doesn't contain, a reminder that "what a company's ad says" and "what's on the current Supplement Facts panel" can drift apart.
• Separate group-level trial results from marketing round-numbers. If a brand cites a specific centimeter or percentage figure, check whether that number actually appears in the trial's published results before taking it at face value.

Safety notes before you add any of these

None of these strains are treatments for obesity, and none of the trials above tested people on GLP-1 medications like semaglutide or tirzepatide. If you're on a prescription weight-loss medication, are pregnant or breastfeeding, or are immunocompromised, talk to your doctor before adding any probiotic, and never stop a prescribed medication to try a supplement instead. If you take an oral medication with specific timing instructions, follow those instructions and ask your pharmacist whether a new supplement needs to be taken separately from it.

References

1. Stenman LK, Lehtinen MJ, Meland N, et al. Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults: Randomized Controlled Trial. EBioMedicine. 2016;13:190-200. PMC5264483
2. IFF Health Sciences. HOWARU® B420 product page. iff.com
3. Metagenics. UltraFlora Control product page. metagenics.com
4. Bariatric Advantage. FloraVantage Control product page. bariatricadvantage.com
5. WonderBiotics. WonderBiotics Probiotics for Weight Management product page. wonderbiotics.com
6. Laue C, Papazova E, Pannenbeckers A, Schrezenmeir J. Effect of a Probiotic and a Synbiotic on Body Fat Mass, Body Weight and Traits of Metabolic Syndrome in Individuals with Abdominal Overweight: A Human, Double-Blind, Randomised, Controlled Clinical Study. Nutrients. 2023;15(13):3039. PMC10346309
7. Culturelle. Metabolism + Weight Management with SlimBiotics® product page. culturelle.com
8. Pedret A, Valls RM, Calderón-Pérez L, et al. Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial. Int J Obes (Lond). 2019;43(9):1863-1868. PMC6760601
9. Seed Health. Daily Synbiotic (DS-01®) reference library, Dermatological Health Blend. seed.com
10. Kadooka Y, Sato M, Imaizumi K, et al. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr. 2010;64(6):636-643. PMID 20216555
11. Kadooka Y, Sato M, Ogawa A, et al. Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial. Br J Nutr. 2013;110(9):1696-1703. PMID 23614897
12. BB Company. Provitalize product page. thebbco.com
13. Kim J, Yun JM, Kim MK, Kwon O, Cho B. Lactobacillus gasseri BNR17 Supplementation Reduces the Visceral Fat Accumulation and Waist Circumference in Obese Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. J Med Food. 2018;21(5):454-461. PMID 29688793
14. NutraIngredients-USA. UAS Labs licenses BNR17 probiotic strain for weight management. 2018. nutraingredients.com
15. Daily Nouri. Weight Health product page. dailynouri.com
16. Physician's Choice. THIN 30 product page. get.physicianschoice.com
17. Sánchez M, Darimont C, Drapeau V, et al. Effect of Lactobacillus rhamnosus CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women. Br J Nutr. 2014;111(8):1507-1519. PMID 24299712